rimegepant
Brand: Nurtec ODT
Prototype: ubrogepant
Drug Class: CGRP receptor antagonist (gepant)
Drug Family: antimigraine
Subclass: small-molecule CGRP receptor antagonist
Organ Systems: cns
Mechanism of Action
Competitively antagonizes the CGRP receptor, blocking the actions of CGRP — a potent vasodilatory neuropeptide released from trigeminal nerve endings during migraine. By blocking CGRP receptor activation, rimegepant reduces trigeminal neuroinflammation and vasodilation. Unlike triptans, has no vasoconstrictive activity.
CGRP receptor (calcitonin gene-related peptide receptor)
Indications
- acute treatment of migraine with or without aura (adults)
- preventive treatment of episodic migraine (adults) — first oral drug approved for both acute and preventive migraine in same formulation
Contraindications
- strong CYP3A4 inhibitors (increase rimegepant levels 4-fold)
- strong CYP3A4 inducers (reduce efficacy)
Adverse Effects
Common
- nausea
- abdominal pain
- urinary tract infection
Serious
- hepatotoxicity (rare in clinical trials)
- hypersensitivity reactions
Pharmacokinetics (ADME)
| Absorption | oral (ODT); bioavailability ~64%; food has minimal effect |
| Distribution | protein binding ~96% |
| Metabolism | primarily CYP3A4; moderate CYP2C9 |
| Excretion | fecal (~77%) and renal (~24%) |
| Half-life | 11 hours |
| Onset | 1-2 hours for acute migraine |
| Peak | 1.5 hours |
| Duration | 24 hours |
| Protein Binding | 96% |
| Vd | not well characterized |
Drug Interactions
| Drug / Agent | Mechanism | Severity |
|---|---|---|
| strong CYP3A4 inhibitors (clarithromycin, itraconazole) | increase rimegepant AUC 4-fold; maximum 1 dose per 48 hours | major |
| strong CYP3A4 inducers (rifampin) | substantially reduce rimegepant levels; avoid | major |
Nursing Considerations
- Unique dual indication: 75 mg acutely for migraine attack; 75 mg every other day for prevention — verify which indication the drug is being used for.
- No cardiovascular contraindications unlike triptans; suitable for patients with CAD, stroke history, or uncontrolled hypertension.
- ODT formulation is placed on/under tongue and dissolves without water; useful for patients with nausea.
- CYP3A4 inhibitors (including many antifungals, macrolide antibiotics) require reducing to 1 dose per 48 hours.
Clinical Pearls
- Rimegepant is the first and only drug FDA-approved for both acute and preventive migraine treatment in the same formulation and dose, eliminating the need for separate medications for patients who need both.
- CGRP pathway drugs represent the first migraine-specific class developed based on understanding of migraine pathophysiology; triptans were discovered before the CGRP mechanism was understood.
Safety Profile
Pregnancy avoid
Lactation avoid
Renal Adjustment Not required
Hepatic Adjustment Required
TDM Not required
Guideline Update pending
Concordance Terms
Cross-referenced clinical concepts — click any term to see all content where it appears.